Nexalin Technology, Inc. announced on May 13, 2025, the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipeline.
The restructured SAB includes Dr. Mingxiong Huang, an expert in neuroimaging; Dr. David Owens, the company’s Chief Medical Officer; and Dr. Abe Scheer, a specialist in adult and pediatric neurology and brain injury medicine. Their combined expertise will guide the company’s scientific direction, clinical strategy, and biomarker-driven trial design for neurodegenerative and neuropsychiatric disorders.
Nexalin’s Gen-2 SYNC and Gen-3 Halo™ headset delivers DIFS™, a proprietary waveform capable of penetrating deep brain structures implicated in cognitive decline. Encouraging published and internal data suggest DIFS™ may promote neuroplasticity and functional recovery. The company plans to initiate new Alzheimer’s-focused clinical studies in the third quarter of 2025, incorporating cognitive testing, imaging biomarkers, and MEG-guided metrics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.